18 news items
Invivyd Announces General Alignment with U.S. FDA on a Repeatable, Expedient Emergency Use Authorization Pathway for the Prevention and Treatment of Symptomatic COVID-19, Based on Compact Clinical Programs to Establish Safety and Immunobridging for Serial Monoclonal Antibodies
IVVD
31 May 24
SARS-CoV-2 variants, including JN.1. PEMGARDA targets the SARS-CoV-2 spike protein receptor binding domain (RBD), thereby inhibiting virus attachment
Invivyd Announces the Appointment of Timothy Lee as Chief Commercial Officer
IVVD
31 May 24
targets the SARS-CoV-2 spike protein receptor binding domain (RBD), thereby inhibiting virus attachment to the human ACE2 receptor on host cells
HC Wainwright & Co. Reiterates Buy on Invivyd, Maintains $15 Price Target
IVVD
24 May 24
HC Wainwright & Co. analyst Patrick Trucchio reiterates Invivyd (NASDAQ:IVVD) with a Buy and maintains $15 price target.
HC Wainwright & Co. Reiterates Buy on Invivyd, Maintains $15 Price Target
IVVD
14 May 24
HC Wainwright & Co. analyst Patrick Trucchio reiterates Invivyd (NASDAQ:IVVD) with a Buy and maintains $15 price target.
Invivyd to Pursue Rapid Immunobridging Pathway to Potential EUA for Treatment of COVID-19 in Moderately to Severely Immunocompromised People, Based on U.S. FDA Feedback
IVVD
7 May 24
targeting the receptor binding domain (RBD) of the SARS-CoV-2 spike protein have been highly effective therapeutic options for symptomatic COVID-19
t5lybe8e9zp
IVVD
15 Apr 24
in target population WALTHAM, Mass., April 15, 2024 (GLOBE NEWSWIRE) -- Invivyd, Inc
vshknrw3o9sf9ip4 kwbg5g8ee2kloaemm87z2govkqwu
IVVD
12 Apr 24
according to estimates from the Centers for Disease Control and Prevention. PEMGARDA targets the SARS-CoV-2 spike protein receptor binding domain (RBD
qb2gpvy16s432mws9bdl9lfj2qg5m1an2izfcgvt8
IVVD
5 Apr 24
Guggenheim analyst Evan Wang upgrades Invivyd (NASDAQ:IVVD) from Neutral to Buy and announces $9 price target.
at6xjzxjur2xycwbnqj776uhtsmzgfixef5q9xzflelgzr7k3031lr71du2
CNK
CRBU
DNUT
5 Apr 24
Neutral to Overweight and raised its price target from $14 to $20.
Forge Global Holdings, Inc
7m6w kpdxzr91ps5j3ruw5kkn04ucfx5d9e9b9k833ka9rg8bfndfg
IVVD
4 Apr 24
according to estimates from the Centers for Disease Control and Prevention. PEMGARDA targets the SARS-CoV-2 spike protein receptor binding domain (RBD
emoudm73vcdl86d43 qzu5nnnzm3qa4xb5oee3
AHG
AKBA
APCX
26 Mar 24
to Overweight and raised the price target from $4 to $10.
Sunnova Energy International Inc
eck3fi 8tzuho7civmew4lresjeq3fxiquru7hi7r65u9delo8its
APPF
CGC
DNUT
26 Mar 24
to Overweight and raised its price target from $4 to $10.
Qurate Retail Inc
iu5hqm2zlp221jm62aiu9uxm xclzib3pz
APCX
BREA
BZFD
26 Mar 24
. Morgan Stanley analyst Maxwell Skor upgraded Invivyd from Equal-Weight to Overweight and raised the price target from $4 to $10
3kg941jhsxeddrpfrthgi1pxu
IVVD
26 Mar 24
Morgan Stanley analyst Maxwell Skor upgrades Invivyd (NASDAQ:IVVD) from Equal-Weight to Overweight and raises the price target from $4 to $10.
ozogdbz55s omdsytu2pgtk9slrnt0g
ABBV
AEHR
AKAN
25 Mar 24
offering.
Target Hospitality Corp. (NASDAQ:TH) jumped 21.3
3lfn671igad6j5wwpz4talikznnycul4zq5q5zbicyy5p6d6lt ihrc
IVVD
25 Mar 24
HC Wainwright & Co. analyst Patrick Trucchio reiterates Invivyd (NASDAQ:IVVD) with a Buy and maintains $15 price target.
nmle8ins9j06k39ol7xg22gwgjnrnz3s htbpvv
IVVD
22 Mar 24
targeting conserved epitopes that could be deployed to keep pace with SARS-CoV-2 viral evolution or other viral threats. With a commitment to serial
jhlbfk8xnjcltagol5189pyzu322jwwp56yloro7z zvtjuwsx31pl
IVVD
22 Mar 24
is designed to enable the rapid, serial generation of durable mAbs targeting conserved epitopes that could be deployed to keep pace with SARS-CoV-2 viral
- Prev
- 1
- Next